As per our research report, the global biosimilars market size was worth USD 6.26 billion in 2021. This figure is forecasted to grow at a remarkable compound annual growth rate (CAGR) of 39.39% and reach USD 32.93 billion by 2026.
According to WHO, A biosimilar is a biological product similar to the already licensed reference biotherapeutic product similar to quality, safety, and efficacy. It is the same as the generic drug, but it contains a biological entity. According to the FDA, FDA-approved biosimilars have been compared to FDA-approved biosimilars, known as the reference product. Reference and biosimilar products are large and generally complex molecules produced by living organisms that are carefully monitored to ensure consistent quality. Biosimilars are copies of drugs similar to biological drugs that have already been authorized (biological reference medicine) and are similar but not identical. The Indian Guidelines define "similar biologics" as a biological product/drug produced by genetic engineering techniques and claimed to be "similar" in terms of safety, efficacy, and quality to the reference biologics authorized by the Drug Controller General of India (DCGI) for safe use in India. The main reason for the development of biosimilar drugs is the patent protection expiry for many biological medicines.
MARKET DRIVERS:
The cost-effective nature of biosimilars and the increasing prevalence of chronic diseases are major drives of the global biosimilars market growth.
Adalimumab (Humira) for rheumatoid arthritis and trastuzumab (Herceptin) for breast cancer are commonly used biologics. According to WHO, chronic disorders such as Diabetes prevalence have increased faster in low-and middle-income countries than in high-income countries. In 2016, an estimated 1.6 million deaths were directly due to diabetes. Another 2.2 million deaths were due to high blood glucose levels in 2012. Asthma was estimated that more than 339 million people worldwide in 2016. Cancer is the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018. Cancer Globally causes about 1 in 6 deaths.
Increasing manufacturing by biopharmaceutical companies globally is another significant contribution to the global biosimilars market growth.
Approximately 100 biopharmaceutical companies are actively involved in the research and development, production, and marketing of biosimilar therapeutic products in India. Rising government initiatives and FDA approval are further expected to add fuel to the growth rate of the biosimilars market. The FDA was given the authority to approve biosimilars, including interchangeable ones, to maintain the biosimilar product's safety, efficacy, and quality.
Furthermore, biosimilars regulations are critical for ensuring the viability and balance between original and biosimilar drugs. Factors such as the rising demand for prescription drugs, especially high-priced patented drugs, contribute to the rising demand for pharmaceutical drugs. Many current biological products, such as Erbitux, Avastin, and Orencia, will see their patents expire, providing an opening for many innovator firms and generic vendors to provide services specifically suited to biosimilars. The demand to cut healthcare spending and the patent expiration of numerous blockbuster products, and a growing number of biosimilar drug approvals by the FDA are expected to drive biosimilars market growth. The launch of new biosimilars, strategic innovations by industry players such as alliances and collaborations, favorable research funding situation, and drug development pressure on pharmaceuticals due to impending patent expiry contribute to the market's rise.
MARKET RESTRAINTS:
Patient safety and medical efficacy are projected to hamper the growth of the market during the assessment period. The high cost of comparison drugs, on the other hand, limits the market growth by increasing the financial pressure on patients and reimbursement service providers. These high prices are a consequence of a lack of economies of scale owing to reduced demand. Biosimilar costs are not as low as generics due to complex biological production processes for individual biosimilars. The most expensive biologics may cost USD 50,000 a year or more. Biologic drugs are more complex to manufacture than generic drugs. Because it’s not as easy to make a biosimilar drug as it is to make a generic version of a brand-name drug, it is due to most of the drugs are made from chemicals and have a known structure. The aforementioned are some of the factors restraining the growth of the biosimilars market.
Impact of COVID-19 on the global biosimilars market:
The impact of COVID-19 on the Biosimilars market may be significant and has posed a major challenge to pharmaceutical companies focusing on biosimilar development. The reduction in FDA approval of non-COVID therapists during the current pandemic is expected to delay product approvals and launches, hindering the market growth. Also, as most clinical trials have been postponed to combat COVID-19 and minimize infection among participants, most pipeline products show a slow pace of research and development activities.
Also, due to lockdown and travel restrictions across the globe, there is a shortage of supply chains and raw materials that would impact biosimilar production. Thus, due to the aforementioned factors, COVID-19 has a significant impact on the market under study. In the coming decade, there would be an increase in the patent expiry of several existing biological drugs, such as Erbitux, Avastin, Orencia, and others, which would provide an opportunity for many innovative companies and generic manufacturers to offer services tailored specifically to biosimilars. Also, factors such as the cost-effective nature of biosimilars, increasing acceptance and acceptance by various stakeholders in need of diversification of technology and business models, the growing prevalence of chronic diseases is expected to drive the global biosimilars market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Product Type, Technology, Disease & Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
The global biosimilars market research report has been segmented and sub-segmented into the product type, technology, disease, and end-user.
Biosimilars Market - By Product Type:
The Recombinant non-glycosylated protein product type holds a significant share of the global biosimilars market based on the product type. Globally, an increase in the development rate of insulin and growth hormone products is boosting the market growth. The market for biosimilars is expected to grow in response to rising cancer incidences. During the forecast period, the Recombinant Glycosylated Protein segment is expected to grow at a fast rate. Biological drugs such as erythropoietin and monoclonal antibodies are predicted to develop this category over this period due to patent expiration.
Biosimilars Market - By Technology:
Based on Technology, recombinant DNA technology is the most lucrative segment among all and estimated to register a healthy growth rate during the forecast period and is responsible for developing biosimilar drugs such as human growth hormones, insulin, and erythropoietin. The bio-ability similar to cure diseases quickly and effectively is enhanced by advanced technology.
During the projected period, monoclonal antibody technology is expected to rise at a 30.0 percent CAGR. The number of monoclonal antibody uses for cancer and autoimmune disorders have resulted in monoclonal antibody technology's rapid development, propelling the market forward.
Biosimilars Market - By Disease:
Based on the disease, oncology disease dominated the market. Owing to the increased availability of lower-cost biosimilar drugs to treat cancer, the Oncology market leads with the largest share of the global biosimilars market. Factors such as drug clearance for various categories of medications, this section is leading. One of the major factors driving the growth of this oncology disease sector is the many oncology drugs available in the cancer care market.
On the other hand, a blood disorder is anticipated to witness significant growth during the forecast period. With delivering earnings, the blood disorders segment is likely to develop. Common diseases such as anemia and hemophilia and promising outcomes from ongoing clinical trials are some of the factors driving the market growth.
Biosimilars Market - By Region:
In 2020, North America held the largest share in the global biosimilars market. It is due to the acceptance of the advanced technologies coming into the market in this region. The introduction of various drugs and products that receive approval from the FDA is expanding the market growth in this region.
Europe region is followed by North America that is influencing the market growth during the period due to the increase in constructional activities on healthcare centers for providing proper care for the patient.
The Asia-Pacific market has the quickest region during recent years and also in the upcoming years. The area is to hit the industry with a CAGR value during the period. The growing annual income of a person per annum in developing countries is accelerating the growth of the biosimilars market.
The Middle East & Africa has to continue their growth rate during the forecast period.
KEY MARKET PARTICIPANTS:
Some of the promising companies dominating the global biosimilars market profiled in the report are Sandoz International GmbH, Wockhardt Ltd, Hospira, Inc., Teva Pharmaceutical Industries Reddy’s Laboratories, Biocon Limited, Mylan, Inc., Zydus Cadila, Celltrion Inc., Roche Diagnostics, and Cipla Ltd. Global industry players are engaging in corporate investments, partnerships, and mergers to maintain their market positions.
RECENT MARKET DEVELOPMENTS:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Protein
5.1.2 Insulin
5.1.3 Human Growth Hormones
5.1.4 Granulocyte Colony-stimulating Factor (G-CSF)
5.1.5 Interferons
5.1.6 Recombinant Glycosylated Proteins
5.1.7 Erythropoietin
5.1.8 Monoclonal Antibodies
5.1.9 Follitropin
5.1.10 Recombinant Peptides
5.1.11 Glucagon
5.1.12 Calcitonin
5.2 By Technology
5.2.1 Mass Spectroscopy
5.2.2 Chromatography
5.2.3 Monoclonal Antibody Technology
5.2.4 Recombinant DNA Technology
5.2.5 Nuclear magnetic resonance (NMR) technology
5.2.6 Electrophoresis
5.2.7 Bioassay
5.3 By Application
5.3.1 Oncology diseases
5.3.2 Blood disorders
5.3.3 Growth hormone deficiencies
5.3.4 Chronic and autoimmune diseases
5.3.5 Others
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Sandoz International GmbH
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Wockhardt
8.3 Hospira
8.4 Teva Pharmaceutical Industries
8.5 Dr. Reddy’s Laboratories
8.6 Biocon
8.7 Mylan
8.8 Zydus Cadila
8.9 Celltrion
8.10 Roche Diagnostics
8.11 Cipla
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Feb 2020
Feb 2020
